Lupin Ltd launched its version of Favipiravir under brand name Covihalt, in India

The Indian Pharmaceuticals major company, Lupin, has launched its version of the antiviral drug Favipiravir to treat the deadly COVI 19 disease. It has been informed by the company in an exchange filing. The drug has been launched with the brand name ‘Covihalt’ for the treatment of mild-to-moderate COVID 19 among the patients. The Drug Controller General of India has also accorded approval to the drug for emergency use.

Details of the Drug by Lupin

A host of other pharma majors in India such as Cipla Limited, Sun Pharma and Hetero Labs have been developing this drug for the treatment of COVID 19. This version of Lupin came amidst the rising number of coronavirus affected patients in the country and it will be available as 200 mg tablets in the form of a strip of 10 tablets with each tablet being priced at Rs 49 by the company. Sun Pharma has also launched its version, which is the cheapest till date, with the price tag of Rs 35 per tablet.

Favipiravir Drug

This is an antiviral drug mainly used for the treatment of influenza in Japan. However, in the wake of the COVID 19 pandemic all over the world, this is also being tried to treat this deadly disease. This drug is used to treat very novel influenza rather than seasonal influenza. It is also observed to have been effective for the treatment of Ebola Virus.




Latest E-Books